Abstract
High serum Mucin-1 (sMUC-1) levels have been shown in patients with adenocarcinoma and multiple myeloma (MM). We evaluated sMUC-1 levels in 76 patients with MM, 6 with plasma cells leukaemia (PCL) and 89 with monoclonal gammopathy of undetermined significance, to establish prevalence data and verify its possible prognostic role. Of the 171 patients, 27 [16%; 95% confidence interval (CI): 10-21%] had high sMUC-1 levels compared with healthy subjects (1.5%; 95% CI: 0-4%). Elevated sMUC-1 levels in MM and PCL patients correlated with anaemia and elevated serum lactate dehydrogenase levels; these patients showed a shorter survival than those with normal sMUC-1 levels (median overall survival: 25 vs. 49 months, P = 0.003).
Original language | English |
---|---|
Pages (from-to) | 772-774 |
Number of pages | 3 |
Journal | British Journal of Haematology |
Volume | 121 |
Issue number | 5 |
DOIs | |
Publication status | Published - Jun 2003 |
Keywords
- CA15.3
- Multiple myeloma
- Overall survival
- Prognostic factors
- sMUC-1
ASJC Scopus subject areas
- Hematology